Norditropin ® is the Novo Nordisk A/S registered trademark for somatropin, a polypeptide hormone of recombinant DNA origin. The hormone is synthesized by a special strain of E. coli bacteria that has been modified by the addition of a plasmid which carries the gene for human growth hormone. Norditropin contains the identical sequence of 191 amino acids constituting the naturally occurring pituitary human growth hormone with a molecular weight of about 22,000 Daltons.
Norditropin cartridges are supplied as solutions in ready-to-administer cartridges or prefilled pens with a volume of 1.5 mL.
Each Norditropin cartridge contains the following:
|
In a study conducted in 18 GHD adult patients, where a SC dose of 0.024 mg/kg or 3 IU/m 2 was given in the thigh, the mean (±SD) C max values of 13.8 (±5.8) and 17.1 (±10.0) ng/mL were obtained for the 4 and 8 mg Norditropin vials, respectively, at approximately 4 to 5 hr. post dose. The mean apparent terminal T 1/2 values were estimated to be approximately 7 to 10 hr. However, the absolute bioavailability for Norditropin after the SC route of administration is currently not known.
Norditropin cartridge formulation is bioequivalent to Norditropin vial formulation.
A total of six randomized, double-blind, placebo-controlled studies were performed. Two representative studies, one in adult onset (AO) GHD patients and a second in childhood onset (CO) GHD patients, are described below.
A single center, randomized, double-blind, placebo-controlled, parallel-group, six month clinical trial was conducted in 31 adults with AO GHD comparing the effects of Norditropin ® (somatropin [rDNA origin] for injection) and placebo on body composition. Patients in the active treatment arm were treated with Norditropin 0.017 mg/kg/day (not to exceed 1.33 mg/day). The changes from baseline in lean body mass (LBM) and percent total body fat (TBF) were measured by total body potassium (TBF) after 6 months.
Treatment with Norditropin produced a significant (p=0.0028) increase from baseline in LBM compared to placebo (Table 1).
|
||||||||||||
Analysis of the treatment difference on the change from baseline in percent TBF revealed a significant decrease (p=0.0004) in the Norditropin-treated group compared to the placebo group (Table 2).
|
||||||||||||
Fifteen (48.4%) of the 31 randomized patients were male. The adjusted mean treatment differences on the increase in LBM and decrease in percent TBF from baseline were larger in males compared to females.
Norditropin also significantly increased serum osteocalcin (a marker of osteoblastic activity).
A single center, randomized, double-blind, placebo-controlled, parallel-group, dose-finding, six month clinical trial was conducted in 49 men with CO GHD comparing the effects of Norditropin and placebo on body composition. Patients were randomized to placebo or one of three active treatment groups (0.008, 0.016, and 0.024 mg/kg/day). Thirty three percent of the total dose to which each patient was randomized was administered during weeks 1-4, 67% during weeks 5-8, and 100% for the remainder of the study. The changes from baseline in LBM and percent TBF were measured by TBP after 6 months.
Treatment with Norditropin produced a significant (p=0.0079) increase from baseline in LBM compared to placebo (pooled data) (Table 3).
|
||||||||||||
Analysis of the treatment difference on the change from baseline in percent TBF revealed a significant decrease (p=0.0048) in the Norditropin-treated groups (pooled data) compared to the placebo group (Table 4).
|
||||||||||||
Norditropin also significantly reduced intraabdominal, extraperitoneal and total abdominal fat volume, waist/hip ratio and LDL cholesterol, and significantly increased serum osteocalcin.
Forty four men were enrolled in an open label follow up study and treated with Norditropin for as long as 30 additional months. During this period, the reduction in waist/hip ratio achieved during the initial six months of treatment was maintained.
Norditropin is indicated for the long-term treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
Norditropin is indicated for the replacement of endogenous growth hormone in adults with growth hormone deficiency who meet either of the following two criteria:
In both of these patient populations, growth hormone deficiency should be confirmed by an appropriate growth hormone stimulation test.
Norditropin is contraindicated in patients with a known hypersensitivity to somatropin or any of its excipients.
In general, somatropin is contraindicated in the presence of active neoplasia. Any preexisting neoplasia should be inactive and its treatment complete prior to instituting therapy with Norditropin. Norditropin should be discontinued if there is evidence of recurrent activity. Since growth hormone deficiency may be an early sign of the presence of a pituitary tumor (or, rarely, other brain tumors), the presence of such tumors should be ruled out prior to initiation of treatment. Norditropin should not be used in patients with any evidence of progression or recurrence of an underlying intracranial space-occupying lesion. Available information suggests that the rate of tumor recurrence is not increased by growth hormone therapy.
Growth hormone should not be initiated to treat patients with acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma or to patients having acute respiratory failure. Two placebo-controlled clinical trials in non-growth hormone deficient adult patients (n=522) with these conditions revealed a significant increase in mortality (41.9% vs. 19.3%) among somatropin treated patients (doses 5.3-8 mg/day) compared to those receiving placebo (see WARNINGS ).
Norditropin is contraindicated in patients with proliferative or preproliferative diabetic retinopathy.
Growth hormone is contraindicated in patients with Prader-Willi syndrome who are severely obese or have severe respiratory impairment (see WARNINGS ). Unless patients with Prader-Willi syndrome also have a diagnosis of growth hormone deficiency, Norditropin is not indicated for the long term treatment of pediatric patients who have growth failure due to genetically confirmed Prader-Willi syndrome.
Norditropin should not be used for growth promotion in pediatric patients with closed epiphyses.
Norditropin ® cartridges (somatropin [rDNA origin] injection) must be used with their corresponding color-coded NordiPen ® delivery device. A Norditropin cartridge must not be inserted into a pen with a different color code.
See CONTRAINDICATIONS for information on increased mortality in patients with acute critical illnesses in intensive care units due to complications following open heart or abdominal surgery, multiple accidental trauma or acute respiratory failure. The safety of continuing growth hormone treatment in patients receiving replacement doses for approved indications who concurrently develop these illnesses has not been established. Therefore, the potential benefit of treatment continuation with growth hormone in patients experiencing acute critical illnesses should be weighed against the potential risk.
There have been reports of fatalities after initiating therapy with growth hormone in pediatric patients with Prader-Willi syndrome who had one or more of the following risk factors: severe obesity, history of upper airway obstruction or sleep apnea, or unidentified respiratory infection. Male patients with one or more of these factors may be at greater risk than females. Patients with Prader-Willi syndrome should be evaluated for signs of upper airway obstruction and sleep apnea before initiation of treatment with growth hormone. If, during treatment with growth hormone, patients show signs of upper airway obstruction (including onset of or increased snoring) and/or new onset sleep apnea, treatment should be interrupted. All patients with Prader-Willi syndrome treated with growth hormone should also have effective weight control and be monitored for signs of respiratory infection, which should be diagnosed as early as possible and treated aggressively (see CONTRAINDICATIONS ). Unless patients with Prader-Willi syndrome also have a diagnosis of growth hormone deficiency, Norditropin is not indicated for the long term treatment of pediatric patients who have growth failure due to genetically confirmed Prader-Willi syndrome.
Norditropin ® cartridges (somatropin [rDNA origin] injection) therapy should be carried out under the regular guidance of a physician who is experienced in the diagnosis and management of pediatric patients with growth hormone deficiency or adult patients with either childhood-onset or adult-onset growth hormone deficiency.
Because somatropin may induce a state of insulin resistance, patients should be observed for evidence of glucose intolerance. Somatropin products should be used with caution in patients with diabetes mellitus or a family history of diabetes mellitus. In patients with diabetes mellitus requiring drug therapy, the dose of insulin and/or oral agent may require adjustment when somatropin therapy is initiated.
Hypothyroidism may develop during Norditropin therapy. Untreated hyothyroidism will jeopardize the response to growth hormone. Therefore, thyroid hormone determinations should be performed periodically during Norditropin administration and thyroid hormone replacement therapy should be initiated when indicated.
In patients with hypopituitarism and multiple hormone deficiencies, standard hormonal replacement therapy should be monitored closely when Norditropin therapy is initiated.
Intracranial hypertension (IH) with papilledema, visual changes, headache, nausea and/or vomiting has been reported in a small number of patients treated with growth hormone products. IH has been reported more frequently after treatment with IGF-I. Symptoms usually occur within the first eight weeks after the initiation of growth hormone therapy. In all reported cases, IH-associated signs and symptoms resolved rapidly after temporary suspension or termination of therapy. Funducscopic examinations should be performed routinely before initiating treatment with Norditropin to exclude preexisting papilledema and periodically during the course of Norditropin therapy. If papilledema is observed by funduscopy during Norditropin treatment, treatment should be stopped. If idiopathic IH is confirmed, treatment with Norditropin can be restarted at a lower dose after IH-associated signs and symptoms have resolved.
Patients with growth hormone deficiency secondary to an intracranial lesion should be evaluated frequently in order to detect progression or recurrence of the underlying disease process.
When growth hormone is administered subcutaneously at the same site over a long period of time, tissue atrophy may result. This can be avoided by rotating the injection site. As is the case with any protein product, local or systemic allergic reactions may occur. Parents/Patient should be informed that such reactions are possible and that prompt medical attention should be sought if allergic reactions occur.
Bone age should be monitored periodically during Norditropin administration, especially in patients who are pubertal and/or receiving concomitant thyroid hormone replacement therapy. Under these circumstances, epiphyseal maturation may progress rapidly.
Concomitant glucocorticoid therapy may inhibit the growth promoting effect of Norditropin. Patients with coexisting ACTH deficiency should have their glucocorticoid replacement dose carefully monitored to avoid an inhibitory effect on growth.
Patients with endocrine disorders, including growth hormone deficiency may have an increased incidence of slipped capital femoral epiphysis. Any child who develops a limp or complains or hip or knee pain during growth hormone therapy should be evaluated.
Progression of scoliosis can occur in children who experience rapid growth. Because growth hormone increases growth rate, patients with a history of scoliosis who are treated with growth hormone should be monitored for progression of scoliosis.
Patients with epiphyseal closure who were treated with growth hormone replacement therapy in childhood should be reevaluated according to the criteria in INDICATIONS AND USAGE before continuation of somatropin therapy at the reduced dose level recommended for growth hormone deficient adults. Fluid retention during growth hormone replacement therapy in adults may occur. Clinical manifestations of fluid retention are usually transient and dose dependent (see ADVERSE REACTIONS ).
Experience with prolonged treatment in adults is limited.
Serum levels of inorganic phosphorus, alkaline phosphatase, and IGF-I may increase after Norditropin therapy.
Concomitant glucocorticoid therapy may inhibit the growth promoting effect of Norditropin. Published in vitro data indicate that growth hormone may be an inducer of cytochrome P450 3A4. When growth hormone is administered in combination with drugs known to be metabolized by cytochrome P450 3A4 hepatic enzymes, it is advisable to monitor the clinical effectiveness of such drugs. However, formal drug interaction studies have not been conducted.
Carcinogenicity, mutagenicity, and fertility studies have not been conducted with Norditropin.
Pregnancy Category C. Animal reproduction studies have not been conducted with Norditropin. It is not known whether Norditropin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Norditropin should be given to a pregnant woman only if clearly needed.
It is not known whether Norditropin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Norditropin is administered to a nursing woman.
The safety and effectiveness of Norditropin in patients aged 65 and over has not been evaluated in clinical studies. Elderly patients may be more sensitive to the action of Norditropin, and may be more prone to develop adverse reactions.
Patients being treated with Norditropin and/or their caregivers should be informed about the potential benefits and risks associated with treatment. If home use is determined to be desirable by the physician, instructions on appropriate use should be given. This information is intended to aid in the safe and effective administration of the medication. It is not a disclosure of all possible adverse or intended effects.
If patients are prescribed Norditropin NordiFlex ® , physicians should instruct patients to read the PATIENT INFORMATION and INSTRUCTIONS FOR USE provided with the Norditropin NordiFlex ® prefilled pen.
If home use is prescribed, a puncture resistant container for the disposal of used needles should be recommended to the patient. Patients and/or caregivers should be thoroughly instructed in the importance of proper disposal and cautioned against any resuse of needles.
As with all protein drugs, a small percentage of patients may develop antibodies to the protein. Growth hormone antibodies with binding capacities lower than 2 mg/L have not been associated with growth attenuation. In some patients, when binding capacity was greater than 2 mg/L, interference with growth response was observed. In clinical trials, patients receiving Norditropin for up to 12 months have been tested for induction of antibodies and 0/358 patients developed antibodies with binding capacities above 2 mg/L. Amongst these patients, 165 had previously been treated with other preparations of growth hormone and 193 were previously untreated naive patients. Any patient with well-documented growth hormone deficiency who fails to respond to Norditropin therapy should be tested for antibodies to human growth hormone and have thyroid function tests performed.
The following adverse events have been reported during clinical studies in growth hormone deficient children: headache, local reactions at the injection site, localized muscle pain, rash, weakness, mild hyperglycemia, glucosuria and arthralgia.
Fluid retention and peripheral edema may occur.
Leukemia has been reported in a small number of growth hormone deficient children treated with growth hormone, including recombinant somatropin, recombinant somatrem and growth hormone of pituitary origin. On the basis of current evidence, experts not been able to conclude that growth hormone therapy per se was responsible for these cases of leukemia. The risk, if any, remains to be established.
Adverse events with an incidence of >/=5% occurring in patients with AO GHD during the 6 month placebo-controlled portion of the largest of the six adult GHD Norditropin trials are presented in Table 5. Peripheral edema, other types of edema, arthralgia, myalgia, and paraesthesia were common in the Norditropin-treated patients and reported much more frequently than in the placebo group. These types of adverse events are thought to be related to the fluid accumulating effects of somatropin. In general, these adverse events were mild and transient in nature. During the placebo-controlled portion of this study, approximately 5% of patients without preexisting diabetes mellitus treated with Norditropin were diagnosed with overt type 2 diabetes mellitus compared with none in the placebo group, consistent with the known hyperglycemic effects of somatropin. Anti-GH antibodies were not detected.
Of note, the doses of Norditropin employed during this study (completed in the mid 1990s) were substantially larger than those currently recommended by the Growth Hormone Research Society, and, more than likely, resulted in a greater than expected incidence of fluid retention- and glucose intolerance-related adverse events. A similar incidence and pattern of adverse events were observed during the other three placebo-controlled AO GHD trials and during the two placebo-controlled CO GHD trials.
[See table below]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The adverse event pattern observed during the open label phase of the study was similar to the one presented above.
Short-term overdosage could lead initially to hypoglycemia and subsequently to hyperglycemia. Moreover, overdose with somatropin is likely to cause fluid retention.
Long-term overdosage could result in signs and symptoms of gigantism and/or acromegaly consistent with the known effects of excess human growth hormone.
The Norditropin dosage and schedule for administration must be individualized for each patient. For the treatment of growth hormone insufficiency in children, a dosage of 0.024-0.034 mg/kg body weight/day, 6-7 times a week, by subcutaneous injection is recommended. The thighs are recommended as the preferred sites of injection and the injection site should be rotated.
Treatment with Norditropin of growth failure due to growth hormone deficiency should be discontinued when the epiphyses are fused. Patients who fail to respond adequately while on Norditropin therapy should be evaluated to determine the cause of unresponsiveness.
For adult growth hormone deficient patients, the recommended dosage at the start of therapy is not more than 0.004 mg/kg/day. The dosage may be increased as tolerated to not more than 0.016 mg/kg/day after approximately 6 weeks. In addition to adverse effects, determination of age- and gender-adjusted serum IGF-I levels and clinical response (e.g., body composition assessments) may be used to help guide dose titration. This approach will tend to result in doses that are larger for women compared with men, and smaller for AO growth hormone deficient patients compared with CO growth hormone deficient patients as well as older and obese patients.
Norditropin cartridges must be administered using the NordiPen injection pen. Each cartridge size has a color-coded corresponding pen which is graduated to deliver the appropriate dose based on the concentration of Norditropin in the cartridge.
Norditropin MUST NOT BE INJECTED if the solution is cloudy or contains particulate matter. Use it only if it is clear and colorless.
Norditropin ® cartridges 5 mg/1.5 mL, 10 mg/1.5 mL, and 15 mg/1.5 mL:
Each cartridge of Norditropin must be inserted into its corresponding NordiPen injection pen. Instructions for delivering the dosage are provided in the NordiPen instruction booklet.
Norditropin Nordiflex ® 5 mg/1.5 mL, 10 mg/1.5 mL, and 15 mg/1.5 mL:
Instructions for delivering the dosage are provided in the PATIENT INFORMATION and INSTRUCTIONS FOR USE leaflet enclosed with the Norditropin Nordiflex ® prefilled pen.
Norditropin ® cartridges (somatropin [rDNA origin] injection) 5 mg/1.5 mL, 10 mg/1.5 mL, and 15 mg/1.5 mL:
Non-injected/unused Norditropin cartridges must be stored at 2-8°C/36-46°F (refrigerator). Do not freeze. Avoid direct light.
Norditropin cartridges retain their biological potency until the date of expiry indicated on the label. After a Norditropin cartridge has been inserted into the NordiPen injector, it must be stored in the pen in the refrigerator and used within 4 weeks. Discard unused portion after 4 weeks.
Norditropin NordiFlex ® (somatropin [rDNA origin] injection) 5 mg/1.5 mL, 10 mg/1.5 mL, and 15 mg/1.5 mL:
Non-injected/unused Norditropin NordiFlex prefilled pens must be stored at 2-8°C/36-46°F (refrigerator). Do not freeze. Avoid direct light.
The Norditropin NordiFlex prefilled pens retain their biological potency until the date of expiry indicated on the label. After the initial injection, Norditropin NordiFlex prefilled pens must be stored in the refrigerator and used within 4 weeks. Discard unused portion after 4 weeks.
Norditropin ® cartridges (somatropin [rDNA origin] injection) 5 mg/1.5 mL, 10 mg/1.5 mL, and 15 mg/1.5 mL:
Norditropin is individually cartoned in 5 mg/1.5 mL, 10 mg/1.5 mL, or 15 mg/1.5 mL cartridges which must be administered using the corresponding color-coded NordiPen ® injection pen.
Norditropin 5 mg/1.5 mL cartridge (orange)
NDC 0169-7768-11
Norditropin 10 mg/1.5 mL cartridge (blue)
NDC 0169-7769-11
Norditropin 15 mg/1.5 mL cartridge (green)
NDC 0169-7770-11
Norditropin NordiFlex ® (somatropin [rDNA origin] injection) 5 mg/1.5 mL, 10 mg/1.5 mL, and 15 mg/1.5 mL:
Norditropin NordiFlex is individually cartoned in 5 mg/1.5 mL, 10 mg/1.5 mL, or 15 mg/1.5 mL prefilled pens.
Norditropin NordiFlex 5 mg/1.5 mL cartridge (orange)
NDC 0169-7704-11
Norditropin NordiFlex 10 mg/1.5 mL cartridge (blue)
NDC 0169-7705-11
Norditropin NordiFlex 15 mg/1.5 mL cartridge (green)
NDC 0169-7708-11
Date of Issue: October 2004
© 2002, 2004 Novo Nordisk Inc.
Novo Nordisk ® , Norditropin ® , NordiPen ® and Norditropin NordiFlex ® are registered trademarks of Novo Nordisk A/S.
For information contact:
Novo Nordisk Inc.
100 College Road West
Princeton, New Jersey 08540, USA
1-888-NOVO-HGH
www.norditropin.com
Manufactured by:
Novo Nordisk A/S
2880 Bagsvaerd, Denmark